Adverse Effects of Anti-PD-1/PD-L1 Therapy in Non-small Cell Lung Cancer

Adverse Effects of Anti-PD-1/PD-L1 Therapy in Non-small Cell Lung Cancer

Currently, immunotherapy has shown great efficacy in clinical trials, and monoclonal antibodies directed against immune checkpoint PD-1/PD-L1 have shown encouraging results in first-line or second-line treatment of non-small cell lung cancer patients. Meanwhile, anti-PD-1/PD-L1 immune checkpoint dru...

Full description

Bibliographic Details
Main Authors: Chaoyue Su, Hui Wang, Yunru Liu, Qiaoru Guo, Lingling Zhang, Jiajun Li, Wenmin Zhou, Yanyan Yan, Xinke Zhou, Jianye Zhang
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-09-01
Series:Frontiers in Oncology
Subjects:
adverse effects
PD-1/PD-L1
immunotherapy
immune checkpoint inhibitor
non-small cell lung cancer
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2020.554313/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2020.554313/full

Similar Items